
Barinthus Biotherapeutics plc (NASDAQ: BRNS) related to its merger with Clywedog Therapeutics, Inc. Under the terms of the proposed transaction, Barinthus shareholders will receive one share of common stock in the new combined company for each American Depository Share or ordinary share owned, and Clywedog shareholders will receive 4.358932 shares of common stock in the new combined company for each common or preferred share owned.